Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control

作者: Neil Chester , David R. Mottram , Thomas Reilly , Mark Powell

DOI: 10.1046/J.1365-2125.2003.01948.X

关键词:

摘要: Aims  To study the elimination of ephedrines with reference to International Olympic Committee (IOC) doping control cut-off levels, following multiple dosing over-the-counter decongestant preparations. Methods  A double-blind was performed in which 16 healthy male volunteers were administered either pseudoephedrine or phenylpropanolamine maximal recommended therapeutic doses over a 36-h period. Urine collected every two hours between 08:00 and 24:00 h at 04:00 h throughout testing period three days. drug levels quantified using high performance liquid chromatography. Side-effects assessed, including heart rate blood pressure, four 20:00 h. Results  Mean (95% CI) total eliminated unchanged 75 (88, 61) 81 (92, 71)%, respectively. Maximum urine concentrations 112.1 (164.2, 59.9) 148.5 (215.0, 82.1) mg.l−1, peak concentration occurred final dose. There no adverse cardiovascular effects only mild CNS stimulation evident. Conclusions  Following therapeutic, dosing, remain above IOC for minimum 6 h 16 h pseudoephedrine, Athletes require informed advice on this from their healthcare professionals.

参考文章(21)
Cheryl L. Zimmerman, Mary Beth O'Connell, Inmaculada Soria, The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine. Pharmaceutical Research. ,vol. 7, pp. 96- 102 ,(1990) , 10.1023/A:1015852012968
Cheryl L. Zimmerman, The effect of urinary pH modification on the disposition of phenylpropanolamine Pharmaceutical Research. ,vol. 5, pp. 120- 122 ,(1988) , 10.1023/A:1015948403476
WA Sorem, RH Dodds, ST Rolfe, A Comparison of the J -lntegral and CTOD Parameters for Short Crack Specimen Testing ASTM special technical publications. pp. 19- 41 ,(1991) , 10.1520/STP16845S
R. Dowse, J.M. Haigh, I. Kanfer, Pharmacokinetics of phenylpropanolamine in humans after a single-dose study International Journal of Pharmaceutics. ,vol. 39, pp. 141- 148 ,(1987) , 10.1016/0378-5173(87)90209-2
C. Bye, H. M. Hill, D. T. D. Hughes, A. W. Peck, A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. European Journal of Clinical Pharmacology. ,vol. 8, pp. 47- 53 ,(1975) , 10.1007/BF00616414
C. BYE, D. DEWSBURY, A.W. PECK, EFFECTS ON THE HUMAN CENTRAL NERVOUS SYSTEM OF TWO ISOMERS OF EPHEDRINE AND TRIPROLIDINE, AND THEIR INTERACTION British Journal of Clinical Pharmacology. ,vol. 1, pp. 71- 78 ,(1974) , 10.1111/J.1365-2125.1974.TB00209.X
K.R. Heimlich, D.R. MacDonnell, T.L. Flanagan, P.D. O'Brien, Evaluation of a sustained release form of phenylpropanolamine hydrochloride by urinary excretion studies. Journal of Pharmaceutical Sciences. ,vol. 50, pp. 232- 237 ,(1961) , 10.1002/JPS.2600500313
Mary Beth O'Connell, Paul R Pentel, Cheryl L Zimmerman, Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation. Clinical Pharmacology & Therapeutics. ,vol. 45, pp. 252- 259 ,(1989) , 10.1038/CLPT.1989.25
Ling Yee Lo, Graham Land, Alan Bye, Sensitive assay for pseudoephedrine and its metabolite, norpseudoephedrine in plasma and urine using gas—liquid chromatography with electron-capture detection Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 222, pp. 297- 302 ,(1981) , 10.1016/S0378-4347(00)81064-6
THOMAS P. BRIGHT, BOBBY W. SANDAGE, H. PATRICK FLETCHER, Selected Cardiac and Metabolic Responses to Pseudoephedrine with Exercise The Journal of Clinical Pharmacology. ,vol. 21, pp. 488- 492 ,(1981) , 10.1002/J.1552-4604.1981.TB05655.X